



Washington D.C.  
Pharmacy Association



## EVIDENCE OF SEX, RACE, AND ETHNICITY DISPARITIES WITH NEW DRUGS: DRUG FORMULARY MANAGEMENT AND UTILIZATION

**Date:** 12/18/2021

**Time:** 7:00 – 8:00 PM

Continuing Pharmacy Education Program  
Clinical Pharmacy Associates, Inc. &  
Washington D.C. Pharmacy Association

**Who should attend:** The program is designed for pharmacists, pharmacy technicians, pharmacy learners and other health care professions responsible for the evaluation of new and emerging drugs and biologicals and the safe, cost-effective use of these products in the care of patients and or populations of people.

**Needs Statement:** Defining and addressing health disparity related to prescription and over the counter medications for underrepresented groups is an important but not well-established area of education, training, and practice within the US (United States) health care systems for pharmacy professionals and other health care providers.

**Statement of Goal:** To provide the successful participant with scientific, clinical and quality improvement information and perspectives on the evidence in underrepresented groups, I.e., sex, race and ethnicity for new drugs and biologicals to advance health equity in pharmaceutical care.

**Activity Type:** Knowledge

**Objectives:** After completing the program, participants should be able to:

- Review evidence from available newer clinical studies for FDA approved drugs in 2019-202 regarding participation of underrepresented groups based on sex, race and ethnicity
- Recognize major trends in participation by underrepresented groups in clinical studies used to gain drug approval by the FDA
- Identify at least 2 reasons underrepresentation of populations in clinical trials exist in the US and recommend at least one action that can be taken to address this disparity
- Discuss the potential impact of underrepresentation of groups in new drug studies on our understanding of their safety, efficacy and use in clinical practice
- Given a case of the newer antiretroviral drugs, Cabenuva and Vocabrio participate in a formulary review discussion about the products evidence regarding sex, race, and ethnicity.

### **Faculty**

Christopher A. Keeys, PharmD, BCPS, R.Ph.  
President and Co-Founder  
Clinical Pharmacy Associates, Inc.  
CEO, MedNovations, Inc.

**Fee:** N/A



® Howard University College of Pharmacy, (COP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of Continuing Professional Education. **This program meets ACPE criteria for one hour (0.10 CEU).** Credit will be awarded through the CPE Monitor, within 3–4 weeks of the seminar to those who successfully complete the program. Using the following URL: <https://hurxce.learningexpressce.com/index.cfm>, the evaluation form and a score  $\geq 70\%$  correct on post-test questions will be required for successful completion. The ACPE Universal Program number assigned to this program is: PENDING